{
  "symbol": "CTSO",
  "company": "Cytosorbents Corporation",
  "generated_at": "2026-06-24T07:36:46.860Z",
  "event_count": 3,
  "events": [
    {
      "type": "pipeline_event",
      "ts": "2026-06-23T14:53:47.493Z",
      "stage": "scout",
      "outcome": "failed",
      "reason": null,
      "trigger": "[form4_cluster] 2 Form 4 filings in last 14 days · 2 real trades (2 buys)",
      "source": "hunter"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-09T09:48:31.493Z",
      "summary": "CTSO is a nano-cap ($26M) medical device company with an FDA-rejected blood purification technology (DrugSorb-ATR). The stock has collapsed ~70% from its 52w high amid twin regulatory setbacks: the FDA denied the De Novo for DrugSorb-ATR twice and Health Canada refused approval, forcing resubmission. The company declared going concern in Q1 2026 with only ~$4.8M unrestricted cash vs. quarterly burn of $3-5M, and faces a Nasdaq minimum bid price delisting notice ($0.41 vs. required $1.00 by September 28, 2026). Revenue is flat (~2% growth to $37M annualized) while the company burns $10M+ annually in cash. No recent CEO/CFO open-market buys; insider cluster buying from January 2025 (~$450K via rights offering participation) represents stale conviction given the stock's subsequent collapse.",
      "verdict": "no_anomaly",
      "confidence": 4,
      "tool_calls": 16,
      "walltime_min": 19,
      "debug_path": "dossiers/2026-06-09-CTSO.scout.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-05-16T01:30:44.038Z",
      "summary": "CytoSorbents is a micro-cap ($31M market cap) medical device company whose flagship CytoSorb blood purification cartridge treats life-threatening critical care and cardiac surgery conditions globally. The stock has collapsed ~49% YTD to near 52-week lows following two FDA De Novo denials for DrugSorb-ATR (April and August 2025), a new $29.3M debt obligation from a structured loan, and persistent operating losses with minimal revenue growth (~1.6%). The FDA proposed an expedited path in late January 2026 pre-sub meeting — but the company is still awaiting clarity on exact submission requirements before filing a new De Novo application. Q1 2026 results (reported May 13) showed modest revenue ($8.9M, +2% YoY) and continued EPS miss (-$0.08 vs -$0.055 est). CEO made one open-market purchase of $64K in November 2025 but no recent director-level cash buys. Options market is extremely illiquid with only two strikes available; IV on the ATM Aug expiry exceeds 234%. The regulatory binary and financial distress make this a speculative situation — not an income candidate given sub-$0.50 price and no dividend.",
      "verdict": "no_anomaly",
      "confidence": 4,
      "tool_calls": 19,
      "walltime_min": 10,
      "debug_path": "dossiers/2026-05-16-CTSO.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "CTSO",
    "call": "SELL",
    "confidence": 2,
    "score": -5,
    "factors": {
      "below_200dma": "-2",
      "below_50dma": "-1",
      "momentum_strong_down": "-2 (-61.7%)",
      "rsi_neutral": "0 (43.2)",
      "macd_above_signal": "+1",
      "recent_macd_bullish_cross": "+1 (4d ago)",
      "broken_below_high": "-2 (-66.7% from high)"
    },
    "summary": "SELL (score -5) · 12-1 mom -61.7% · RSI 43.2 · below_both · -66.7% from high",
    "last_close": 0.43,
    "one_month_ago_close": 0.46,
    "twelve_month_ago_close": 1.2,
    "twelve_one_momentum_pct": -61.67,
    "rsi_14": 43.2,
    "ma_stack": "below_both",
    "from_period_high_pct": -66.74,
    "period_high": 1.29,
    "price_targets": {
      "bear": 0.69,
      "fair": 1.28,
      "bull": 5,
      "bear_return_pct": 60.8,
      "fair_return_pct": 197.9,
      "bull_return_pct": 1065.5,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": 0.75,
        "target_mean": 2.875,
        "target_high": 5,
        "analyst_count": 2
      }
    },
    "generated_at": "2026-06-24T07:36:46.854Z"
  }
}